Literature DB >> 15871997

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

M-F Yuen1, H-J Yuan, D K-H Wong, J C-H Yuen, W-M Wong, A O-O Chan, B C-Y Wong, K-C Lai, C-L Lai.   

Abstract

BACKGROUND: Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for setting up treatment criteria. AIM: To determine risk factors for the development of complications in Asian CHB patients. PATIENTS AND METHODS: A total of 3233 Chinese CHB patients (mean follow up 46.8 months) were monitored for liver biochemistry, viral serology, hepatitis B virus (HBV) DNA levels, acute exacerbation, hepatitis B e antigen (HBeAg) seroconversion, and development of cirrhotic complications and hepatocellular carcinoma.
RESULTS: Median age for HBeAg seroconversion and development of complications was 35 years and 57.2 years, respectively. Patients with alanine aminotransferase (ALT) levels of 0.5-1 times the upper limit of normal (ULN) and 1-2x ULN had an increased risk for the development of complications compared with patients with ALT levels <0.5x ULN (p<0.0001 for both). HBeAg/antibody to hepatitis B e antigen status, and number of episodes, duration, and peak ALT levels of acute exacerbations were not associated with an increased risk of complications. In patients with complications, 43.6% had HBV DNA levels less than 1.42x10(5) copies/ml. Male sex, stigmata of chronic liver disease, old age, low albumin, and high alpha fetoprotein levels on presentation were independently associated with increased cumulative risk of complications. Male sex, presence of hepatitis symptoms, old age, low albumin level, and presence of complications on presentation were independently associated with shorter survival.
CONCLUSION: Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5-2x ULN, is the most likely pathway for the development of complications in Asian CHB patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871997      PMCID: PMC1774768          DOI: 10.1136/gut.2005.065136

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

Review 1.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

Authors: 
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

Review 2.  Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.

Authors:  Yun-Fan Liaw; Nancy Leung; Richard Guan; George K K Lau; Ismail Merican
Journal:  J Gastroenterol Hepatol       Date:  2003-03       Impact factor: 4.029

3.  Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

Authors:  Man-Fung Yuen; Erwin Sablon; He-Jun Yuan; Chee-Kin Hui; Danny Ka-Ho Wong; Joke Doutreloigne; Benjamin Chun-Yu Wong; Annie On-On Chan; Ching-Lung Lai
Journal:  J Infect Dis       Date:  2002-10-11       Impact factor: 5.226

Review 4.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

Review 5.  The natural history of hepatitis B virus infection.

Authors:  A L Eddleston
Journal:  Chemioterapia       Date:  1988-12

6.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Authors:  Ching-Lung Lai; Mohamed Rosmawati; Judy Lao; Hans Van Vlierberghe; Frank H Anderson; Neal Thomas; Deborah Dehertogh
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

7.  The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Authors:  Y F Liaw; D I Tai; C M Chu; T J Chen
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

Review 8.  Natural history of chronic hepatitis B virus infection: new light on an old story.

Authors:  D S Chen
Journal:  J Gastroenterol Hepatol       Date:  1993 Sep-Oct       Impact factor: 4.029

9.  Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.

Authors:  Chi-Jen Chu; Munira Hussain; Anna S F Lok
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

10.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17
View more
  100 in total

1.  Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

Authors:  Moon Seok Choi; Byung Chul Yoo
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

2.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

Review 3.  Predicting survival in hepatitis B.

Authors:  M Sherman
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

Review 4.  Antiviral therapy and resistance with hepatitis B virus infection.

Authors:  Hans L Tillmann
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

5.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

6.  Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients.

Authors:  Shehab Mahmoud Abd El-Kader; Mohammed H Saiem Al-Dahr
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

7.  Low treatment rates in patients meeting guideline criteria in diverse practice settings.

Authors:  Lily H Kim; Vincent G Nguyen; Huy N Trinh; Jiayi Li; Jian Q Zhang; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2014-07-25       Impact factor: 3.199

8.  Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection.

Authors:  Elegance Ting Pui Lam; Cindy Lo Kuen Lam; Ching Lung Lai; Man Fung Yuen; Daniel Yee Tak Fong
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

9.  A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

Authors:  Myron John Tong; Leeyen Hsu; Carlos Hsien; Jia-Horng Kao; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt
Journal:  Hepatol Int       Date:  2010-04-07       Impact factor: 6.047

10.  Health-related quality of life of Southern Chinese with chronic hepatitis B infection.

Authors:  Elegance T P Lam; Cindy L K Lam; C L Lai; M F Yuen; Daniel Y T Fong; Thomas M K So
Journal:  Health Qual Life Outcomes       Date:  2009-06-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.